Pathkey.AI Secures Largest Client Deal With Imunexus Services Agreement
Pathkey.AI has executed a Services Agreement with Imunexus Therapeutics Limited, marking the company’s largest commercial engagement to date with a potential value of up to A$100,000 + GST. The Pathkey.AI Imunexus Commercial Contract includes an immediate payment of A$25,000 + GST upon execution, with the remaining A$75,000 + GST contingent on Imunexus completing future capital raisings, payable in three milestone-based tranches. The agreement is effective from 1 April 2026 with an initial one-year term.
This engagement represents tangible proof of (ASX: PKY)’s ability to convert platform capability into revenue-generating client relationships. The agreement is expected to contribute to FY26 and FY27 revenue, providing immediate financial benefit whilst establishing a foundation for potential expansion subject to the terms of the contract.
Pathkey.AI lands commercial breakthrough with Imunexus deal
The Services Agreement marks a significant step in the company’s commercialisation strategy, demonstrating real-world adoption of its TrialKey platform by a third-party biotechnology company. The immediate A$25,000 + GST payment provides near-term revenue, whilst the structure of contingent tranches creates potential for expanded engagement as the client relationship develops.
The agreement may be terminated by either party on 14 days’ written notice, or earlier in certain circumstances including material breach or insolvency. Whilst a portion of the contract value depends on Imunexus undertaking future capital raising activities, the phased structure enables the company to establish initial engagement and demonstrate value before expanded deployment.
When big ASX news breaks, our subscribers know first
What is Pathkey’s TrialKey platform?
TrialKey is an AI-powered decision-support system designed to assist biotechnology and pharmaceutical companies throughout the clinical development process. The platform combines machine learning, large language models and reasoning-based systems to address complex challenges in drug development.
At its core, TrialKey transforms large volumes of unstructured data into structured, model-ready inputs that support predictive analytics and optimisation. In practical terms, this means the platform can analyse clinical trial information, regulatory data and historical outcomes to help companies assess the likelihood of trial success and identify ways to improve trial design before execution.
For biotechnology companies like Imunexus, this capability addresses high-cost, high-complexity problems inherent in drug development. Clinical trials represent substantial capital investment with significant execution risk. By providing data-driven insights into probability of success and trial optimisation opportunities, TrialKey aims to help clients make more informed decisions about resource allocation and trial design.
The platform’s ability to benchmark pipeline assets against global clinical trial datasets provides clients with comparative context for their development programs, supporting both internal planning and external communications with investors.
How Imunexus will deploy the technology
The engagement is structured across two sequential phases, enabling progressive integration and expanding use cases over time.
| Phase | Scope | Key Deliverables |
|---|---|---|
| Step 1: Pilot & Baseline | Integration of Imunexus pipeline into TrialKey | Baseline analytics for clinical planning and capital raising preparation |
| Step 2: Clinical Alignment | Protocol refinement | CRO proposal integration, ongoing AI-driven reporting |
Imunexus is deploying TrialKey across multiple high-value use cases that span both scientific and commercial workflows. The platform is being applied to assess probability of success and development risk for the company’s pipeline assets, providing quantitative inputs for decision-making around trial progression.
In early-phase clinical trial design, TrialKey will be used to optimise protocol parameters prior to execution. This includes benchmarking Imunexus assets against global clinical trial datasets to identify comparative positioning and potential optimisation opportunities.
The platform will also support investor communications and future capital raising positioning, demonstrating its dual application across both scientific processes and capital markets workflows. This expanded addressable use case increases the potential for recurring engagement as Imunexus progresses through development milestones.
During the Clinical Alignment phase, TrialKey insights will be integrated into contract research organisation (CRO) requests for proposals, with ongoing AI-driven reporting supporting continuous optimisation throughout trial execution.
Director commentary
Damon Rasheed, Executive Director
“This agreement with Imunexus is an important commercial milestone and the largest engagement secured by Pathkey to date. It demonstrates the real-world application of our technology across both clinical development and capital markets, and importantly, our ability to convert this capability into revenue. We see significant opportunity to replicate this model across additional clients as demand for data-driven decision support continues to grow.”
The next major ASX story will hit our subscribers first
Commercial validation and revenue outlook
The Imunexus engagement provides tangible proof of the company’s commercialisation strategy, transitioning from platform development to revenue generation through paying client relationships. The agreement validates the proposition that biotechnology companies will embed third-party AI decision-support tools into live clinical development workflows.
Management has noted the engagement is expected to contribute to FY26 and FY27 revenue, providing near-term financial benefit whilst demonstrating a repeatable model for customer acquisition. The company sees opportunity to replicate this approach across additional clients as demand for data-driven decision support continues to grow in the clinical development sector.
The platform’s dual application across scientific processes and capital markets workflows expands the addressable customer base beyond pharmaceutical and biotechnology companies to include advisory sectors involved in biotech investment and capital raising.
Key contract terms are structured as follows:
- Total potential value: up to A$100,000 + GST
- Immediate payment: A$25,000 + GST upon execution
- Contingent tranches: A$75,000 + GST tied to Imunexus capital raisings
- Term: One year, terminable on 14 days’ notice
Whilst contingent payments introduce execution risk dependent on Imunexus capital raising activities, the immediate revenue component and phased structure create a foundation for potential longer-term relationships. The contract demonstrates customer acquisition capability whilst validating the commercial model for future engagements.
The global clinical development sector represents a significant and growing market, with increasing demand for technologies that improve trial efficiency, reduce risk and support investment decision-making. As the company continues to convert early engagements into revenue-generating contracts, it is building a pipeline of commercial opportunities across this addressable market.
About Imunexus Therapeutics
Imunexus Therapeutics Limited is a biotechnology company developing novel immunotherapies for neuroinflammatory and autoimmune diseases, with an initial focus on multiple sclerosis. The company is advancing early-stage clinical programs.
Want the Next AI Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX Tech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements drop.